Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Anixa Biosciences Inc stock logo
ANIX
Anixa Biosciences
$3.19
+1.6%
$2.98
$2.07
$4.20
$102.75M0.39104,706 shs106,867 shs
Contineum Therapeutics, Inc. stock logo
CTNM
Contineum Therapeutics
$4.01
+2.3%
$4.05
$3.35
$21.92
$103.77M0.8590,246 shs17,424 shs
Procaps Group S.A. stock logo
PROC
Procaps Group
$0.95
-40.3%
$0.95
$0.50
$3.78
$107.18M-0.0556,324 shs658,169 shs
SCYNEXIS, Inc. stock logo
SCYX
SCYNEXIS
$0.70
-1.0%
$0.83
$0.66
$2.29
$27.43M1.57161,606 shs142,354 shs
7 Energy Stocks to Buy and Hold Forever Cover

With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Anixa Biosciences Inc stock logo
ANIX
Anixa Biosciences
-2.18%-2.79%+13.77%+16.73%+38.33%
Contineum Therapeutics, Inc. stock logo
CTNM
Contineum Therapeutics
+2.89%+1.82%-17.47%-15.15%-81.24%
Procaps Group S.A. stock logo
PROC
Procaps Group
0.00%0.00%0.00%0.00%-62.00%
SCYNEXIS, Inc. stock logo
SCYX
SCYNEXIS
+0.37%+1.34%-22.61%-17.51%-63.00%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Anixa Biosciences Inc stock logo
ANIX
Anixa Biosciences
2.644 of 5 stars
3.63.00.00.01.13.30.0
Contineum Therapeutics, Inc. stock logo
CTNM
Contineum Therapeutics
2.1628 of 5 stars
3.61.00.00.00.00.81.3
Procaps Group S.A. stock logo
PROC
Procaps Group
N/AN/AN/AN/AN/AN/AN/AN/A
SCYNEXIS, Inc. stock logo
SCYX
SCYNEXIS
0.258 of 5 stars
0.03.00.00.00.00.80.6
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Anixa Biosciences Inc stock logo
ANIX
Anixa Biosciences
3.25
Buy$9.00182.13% Upside
Contineum Therapeutics, Inc. stock logo
CTNM
Contineum Therapeutics
3.17
Buy$22.50461.10% Upside
Procaps Group S.A. stock logo
PROC
Procaps Group
0.00
N/AN/AN/A
SCYNEXIS, Inc. stock logo
SCYX
SCYNEXIS
0.00
N/AN/AN/A

Current Analyst Ratings Breakdown

Latest SCYX, PROC, CTNM, and ANIX Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
6/20/2025
Contineum Therapeutics, Inc. stock logo
CTNM
Contineum Therapeutics
William Blair
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageOutperform
6/10/2025
Anixa Biosciences Inc stock logo
ANIX
Anixa Biosciences
D. Boral Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$10.00
5/29/2025
Anixa Biosciences Inc stock logo
ANIX
Anixa Biosciences
D. Boral Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$10.00
5/19/2025
Contineum Therapeutics, Inc. stock logo
CTNM
Contineum Therapeutics
Morgan Stanley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOverweight ➝ Overweight$25.00 ➝ $20.00
5/15/2025
Contineum Therapeutics, Inc. stock logo
CTNM
Contineum Therapeutics
Royal Bank Of Canada
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOutperform ➝ Outperform$31.00 ➝ $31.00
4/10/2025
Anixa Biosciences Inc stock logo
ANIX
Anixa Biosciences
D. Boral Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$10.00 ➝ $10.00
(Data available from 7/9/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Anixa Biosciences Inc stock logo
ANIX
Anixa Biosciences
$210K489.29N/AN/A$0.59 per share5.41
Contineum Therapeutics, Inc. stock logo
CTNM
Contineum Therapeutics
$50M2.07N/AN/A$7.66 per share0.52
Procaps Group S.A. stock logo
PROC
Procaps Group
$409.92M0.26N/AN/AN/A
SCYNEXIS, Inc. stock logo
SCYX
SCYNEXIS
$3.75M7.31N/AN/A$1.45 per share0.48
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Anixa Biosciences Inc stock logo
ANIX
Anixa Biosciences
-$12.55M-$0.38N/AN/AN/A-68.17%-60.38%9/5/2025 (Estimated)
Contineum Therapeutics, Inc. stock logo
CTNM
Contineum Therapeutics
-$42.26M-$1.97N/AN/AN/AN/A-24.59%-23.49%8/12/2025 (Estimated)
Procaps Group S.A. stock logo
PROC
Procaps Group
$42.54MN/A0.00N/AN/AN/AN/AN/A
SCYNEXIS, Inc. stock logo
SCYX
SCYNEXIS
-$21.29M-$0.56N/A14.06N/A-1,030.04%-53.47%-32.86%8/6/2025 (Estimated)

Latest SCYX, PROC, CTNM, and ANIX Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
6/3/2025Q2 2025
Anixa Biosciences Inc stock logo
ANIX
Anixa Biosciences
-$0.10-$0.09+$0.01-$0.09N/AN/A
5/15/2025Q1 2025
SCYNEXIS, Inc. stock logo
SCYX
SCYNEXIS
-$0.23-$0.17+$0.06-$0.11$0.14 million$0.26 million
5/14/2025Q1 2025
Contineum Therapeutics, Inc. stock logo
CTNM
Contineum Therapeutics
-$0.56-$0.62-$0.06-$0.62$7.50 millionN/A
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Anixa Biosciences Inc stock logo
ANIX
Anixa Biosciences
N/AN/AN/AN/AN/A
Contineum Therapeutics, Inc. stock logo
CTNM
Contineum Therapeutics
N/AN/AN/AN/AN/A
Procaps Group S.A. stock logo
PROC
Procaps Group
N/AN/AN/AN/AN/A
SCYNEXIS, Inc. stock logo
SCYX
SCYNEXIS
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Anixa Biosciences Inc stock logo
ANIX
Anixa Biosciences
N/A
8.89
8.89
Contineum Therapeutics, Inc. stock logo
CTNM
Contineum Therapeutics
N/A
21.47
21.47
Procaps Group S.A. stock logo
PROC
Procaps Group
N/AN/AN/A
SCYNEXIS, Inc. stock logo
SCYX
SCYNEXIS
N/A
5.83
5.83

Institutional Ownership

CompanyInstitutional Ownership
Anixa Biosciences Inc stock logo
ANIX
Anixa Biosciences
29.13%
Contineum Therapeutics, Inc. stock logo
CTNM
Contineum Therapeutics
N/A
Procaps Group S.A. stock logo
PROC
Procaps Group
N/A
SCYNEXIS, Inc. stock logo
SCYX
SCYNEXIS
54.37%

Insider Ownership

CompanyInsider Ownership
Anixa Biosciences Inc stock logo
ANIX
Anixa Biosciences
25.30%
Contineum Therapeutics, Inc. stock logo
CTNM
Contineum Therapeutics
11.30%
Procaps Group S.A. stock logo
PROC
Procaps Group
19.90%
SCYNEXIS, Inc. stock logo
SCYX
SCYNEXIS
4.86%
CompanyEmployeesShares OutstandingFree FloatOptionable
Anixa Biosciences Inc stock logo
ANIX
Anixa Biosciences
532.21 million24.06 millionOptionable
Contineum Therapeutics, Inc. stock logo
CTNM
Contineum Therapeutics
3125.87 million22.95 millionN/A
Procaps Group S.A. stock logo
PROC
Procaps Group
4,900112.82 million90.37 millionNot Optionable
SCYNEXIS, Inc. stock logo
SCYX
SCYNEXIS
6039.02 million37.12 millionOptionable

Recent News About These Companies

SCYNEXIS Resumes Patient Dosing in Phase 3 MARIO Study
Scynexis to present preclinical data on SCY-247 at ESCMID Meeting
SCYNEXIS Full Year 2024 Earnings: Misses Expectations
Maxim Group Keeps Their Buy Rating on SCYNEXIS (SCYX)
Federated Hermes, Inc. Expands Stake in SCYNEXIS Inc

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
Anixa Biosciences stock logo

Anixa Biosciences NASDAQ:ANIX

$3.19 +0.05 (+1.59%)
As of 12:19 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Anixa Biosciences, Inc., a biotechnology company, develops therapies and vaccines focusing on critical unmet needs in oncology and infectious diseases. The company's therapeutics programs include the development of a chimeric endocrine receptor T-cell therapy, a novel form of chimeric antigen receptor T-cell (CAR-T) technology focusing on the treatment of ovarian cancer. Its vaccine programs comprise the development of a vaccine against triple negative breast cancer; and a preventative vaccine against ovarian cancer. The company is also developing immuno-therapy drugs against cancer. The company was formerly known as ITUS Corporation and changed its name to Anixa Biosciences, Inc. in October 2018. Anixa Biosciences, Inc. was incorporated in 1982 and is based in San Jose, California.

Contineum Therapeutics stock logo

Contineum Therapeutics NASDAQ:CTNM

$4.01 +0.09 (+2.30%)
As of 12:21 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Contineum Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on discovering and developing novel oral small molecule therapies for neuroscience, inflammation, and immunology indications with high unmet need. Its lead asset is PIPE-791, a novel, brain penetrant, small molecule inhibitor of the lysophosphatidic acid 1 receptor (LPA1R) for the treatment of idiopathic pulmonary fibrosis and progressive multiple sclerosis (MS). The company also develops PIPE-307, a novel, small molecule selective inhibitor of the muscarinic type 1 M1 receptor to treat depression and relapse remitting MS; and CTX-343, a peripherally-restricted LPA1R antagonist. Contineum Therapeutics, Inc. was formerly known as Pipeline Therapeutics, Inc. and changed its name to Contineum Therapeutics, Inc. in November 2023. The company was incorporated in 2009 and is headquartered in San Diego, California.

Procaps Group stock logo

Procaps Group NASDAQ:PROC

$0.95 -0.64 (-40.28%)
Closing price 02/3/2025
Extended Trading
$0.95 0.00 (0.00%)
As of 02/3/2025 07:50 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Procaps Group S.A. develops, produces, and markets pharmaceutical solutions worldwide. The company formulates, manufactures, and markets branded prescription drugs in various therapeutic areas, including feminine care products, pain relief, skin care, digestive health, growth and development, cardiology, vision care, central nervous system, and respiratory. It also provides drugs for hospital use, such as antibiotic, blood clot, personal protective equipment, immunosuppressant, oncology, and analgesics products. In addition, the company offers over-the-counter (OTC) consumer healthcare products through a portfolio on approximately eight therapeutic areas, including gastrointestinal, skin care, cough and cold, analgesics, urological, vitamins, minerals, and supplements in the categories of antibiotics, anti-infective, anti-parasitic, cardiovascular, feminine care, cutaneous antimycotic, pain killers, gastro intestinal, hormonals, metabolic, endocrine, nervous system, ophthalmic, osteoarticular, respiratory, diet supplements, and vitamins and minerals. Further, it provides blood glucose meters, telemonitoring products, oral anti-diabetics products, cosmeceuticals, insulin delivery systems, and other diabetes solutions; and contract drug development and manufacturing services to third party pharmaceutical companies, specializing in soft gelatin capsule technologies. The company was founded in 1977 and is based in Luxembourg, Luxembourg.

SCYNEXIS stock logo

SCYNEXIS NASDAQ:SCYX

$0.70 -0.01 (-1.04%)
As of 12:17 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

SCYNEXIS, Inc., a biotechnology company, develops medicines to overcome and prevent difficult-to-treat and drug-resistant infections in the United States. It offers BREXAFEMME for the treatment of patients with vulvovaginal candidiasis (VVC) and recurrent VVC. The company's lead product candidate is Ibrexafungerp, an intravenous drug for the treatment of invasive candidiasis and/or candidemia, refractory invasive fungal infections, invasive aspergillosis, VVC, and recurrent VVC. It also develops SCY-247 to treat systemic fungal diseases. The company has licensing and collaboration agreements with GlaxoSmithKline Intellectual Property (No. 3) Limited, Merck Sharp & Dohme Corp., Hansoh (Shanghai) Health Technology Co., Ltd., Jiangsu Hansoh Pharmaceutical Group Company Limited, and R-Pharm, CJSC for the development, manufacture, and commercialization of ibrexafungerp. SCYNEXIS, Inc. was formerly known as SCYNEXIS Chemistry & Automation, Inc. and changed its name to SCYNEXIS, Inc. in June 2002. The company was incorporated in 1999 and is headquartered in Jersey City, New Jersey.